Due Diligence at its finest
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$CBIS - Cannabis Science issues CBN patent and R&D guidance for the 2nd quarter of 2014 to its shareholders
http://www.stockwatch.com/News/Item.aspx?bid=U-prLA33628-U%3aCBIS-20140522&symbol=CBIS®ion=U
$CBIS - Cannabis Science issues CBN patent and R&D guidance for the 2nd quarter of 2014 to its shareholders
http://www.stockwatch.com/News/Item.aspx?bid=U-prLA33628-U%3aCBIS-20140522&symbol=CBIS®ion=U
$PPCH - Propanc Scientific Findings Published in Peer Reviewed Cancer Journal
2014-05-21 22:49 ET
MELBOURNE, Australia, May 21, 2014 (GLOBE NEWSWIRE) -- Propanc Health Group Corporation (OTCQB:PPCH) ("Propanc Health Group", "Propanc" or "the Company"), a developmental stage healthcare company focused on new cancer treatments for patients with solid tumors, announced requests for information regarding the anti-cancer effects of its pancreatic proenzymes treatment ("PRP"), can be accessed via Cellular Oncology, a peer reviewed journal of the International Society for Cellular Oncology.
"We have received queries regarding the anti-cancer effects and mechanism of action of proenzymes, which we published last year in collaboration with our research partners," said James Nathanielsz, Chief Executive Officer of Propanc Health Group, "Publishing these findings was an important step to gain credibility within the scientific community who recognize the potential of pancreatic proenzymes as a treatment for metastatic cancer."
Propanc Health Group and its research partners identified that pancreatic proenzymes are able to suppress a long-silent, embryonic program reactivated by cancer cells, called the Epithelial Mesenchymal Transition, or EMT, by returning cancer cells back towards normal behavior. This is important because certain cancer cells develop traits such as motility, invasiveness and a resistance to readily dying. They also become "stem-cell" like and develop the ability to seed new tumors. This process, called metastasis, is responsible for approximately 90% of deaths from cancer.
"From our research we observed that pancreatic proenzymes enforce the re-entry of cancer cells into normal cellular pathways and as such, could represent an exciting new method of managing the disease process," said Dr Julian Kenyon, Chief Scientific Officer of Propanc Health Group, "We believe this small but significant step supports my initial observations from clinical practice that pancreatic proenzymes have the potential to prolong life and stop tumors from spreading, especially if we treat patients during earlier stages of the disease process".
It is anticipated a number of companies developing cancer stem cell therapies will be presenting at the upcoming 2014 ASCO (American Society of Clinical Oncologists) conference. New effective therapies against cancer stem cells attract significant attention due to their potential to control and inhibit metastatic cancer, an area where most cancer drugs often fail.
Propanc Health Group shares a joint intellectual property ownership arrangement with its research partner, the University of Bath, and patents are currently being prosecuted in countries around the world.
Propanc Health Group further aims to fast track the development of proenzyme related oncology products into clinical trials, initially for colorectal and pancreatic tumors. The world market for colorectal cancer is expected to reach $8.8 billion by 2020 and the global pancreatic cancer market is projected to exceed $1.6 billion by 2017, according to research reports.
The Company's scientific publication can be sourced from Cellular Oncology, July 2013, volume 36 (Issue 4), or purchased via the following link: http://link.springer.com/article/10.1007%2Fs13402-013-0134-8.
$PPCH - Propanc Scientific Findings Published in Peer Reviewed Cancer Journal
2014-05-21 22:49 ET
MELBOURNE, Australia, May 21, 2014 (GLOBE NEWSWIRE) -- Propanc Health Group Corporation (OTCQB:PPCH) ("Propanc Health Group", "Propanc" or "the Company"), a developmental stage healthcare company focused on new cancer treatments for patients with solid tumors, announced requests for information regarding the anti-cancer effects of its pancreatic proenzymes treatment ("PRP"), can be accessed via Cellular Oncology, a peer reviewed journal of the International Society for Cellular Oncology.
"We have received queries regarding the anti-cancer effects and mechanism of action of proenzymes, which we published last year in collaboration with our research partners," said James Nathanielsz, Chief Executive Officer of Propanc Health Group, "Publishing these findings was an important step to gain credibility within the scientific community who recognize the potential of pancreatic proenzymes as a treatment for metastatic cancer."
Propanc Health Group and its research partners identified that pancreatic proenzymes are able to suppress a long-silent, embryonic program reactivated by cancer cells, called the Epithelial Mesenchymal Transition, or EMT, by returning cancer cells back towards normal behavior. This is important because certain cancer cells develop traits such as motility, invasiveness and a resistance to readily dying. They also become "stem-cell" like and develop the ability to seed new tumors. This process, called metastasis, is responsible for approximately 90% of deaths from cancer.
"From our research we observed that pancreatic proenzymes enforce the re-entry of cancer cells into normal cellular pathways and as such, could represent an exciting new method of managing the disease process," said Dr Julian Kenyon, Chief Scientific Officer of Propanc Health Group, "We believe this small but significant step supports my initial observations from clinical practice that pancreatic proenzymes have the potential to prolong life and stop tumors from spreading, especially if we treat patients during earlier stages of the disease process".
It is anticipated a number of companies developing cancer stem cell therapies will be presenting at the upcoming 2014 ASCO (American Society of Clinical Oncologists) conference. New effective therapies against cancer stem cells attract significant attention due to their potential to control and inhibit metastatic cancer, an area where most cancer drugs often fail.
Propanc Health Group shares a joint intellectual property ownership arrangement with its research partner, the University of Bath, and patents are currently being prosecuted in countries around the world.
Propanc Health Group further aims to fast track the development of proenzyme related oncology products into clinical trials, initially for colorectal and pancreatic tumors. The world market for colorectal cancer is expected to reach $8.8 billion by 2020 and the global pancreatic cancer market is projected to exceed $1.6 billion by 2017, according to research reports.
The Company's scientific publication can be sourced from Cellular Oncology, July 2013, volume 36 (Issue 4), or purchased via the following link: http://link.springer.com/article/10.1007%2Fs13402-013-0134-8.
$PPCH - Propanc Health Group shares a joint intellectual property ownership arrangement with its research partner, the University of Bath, and patents are currently being prosecuted in countries around the world. http://www.stockwatch.com/News/Item.aspx?bid=U-z10082871-U%3aPPCH-20140521&symbol=PPCH®ion=U
$PPCH - Propanc Health Group shares a joint intellectual property ownership arrangement with its research partner, the University of Bath, and patents are currently being prosecuted in countries around the world. http://www.stockwatch.com/News/Item.aspx?bid=U-z10082871-U%3aPPCH-20140521&symbol=PPCH®ion=U
$PPCH believes this small but significant step supports my initial observations from clinical practice that pancreatic proenzymes have the potential to prolong life and stop tumors from spreading, especially if we treat patients during earlier stages of the disease process".
It is anticipated a number of companies developing cancer stem cell therapies will be presenting at the upcoming 2014 ASCO (American Society of Clinical Oncologists) conference. New effective therapies against cancer stem cells attract significant attention due to their potential to control and inhibit metastatic cancer, an area where most cancer drugs often fail. http://www.stockwatch.com/News/Item.aspx?bid=U-z10082871-U%3aPPCH-20140521&symbol=PPCH®ion=U
$PPCH believes this small but significant step supports my initial observations from clinical practice that pancreatic proenzymes have the potential to prolong life and stop tumors from spreading, especially if we treat patients during earlier stages of the disease process".
It is anticipated a number of companies developing cancer stem cell therapies will be presenting at the upcoming 2014 ASCO (American Society of Clinical Oncologists) conference. New effective therapies against cancer stem cells attract significant attention due to their potential to control and inhibit metastatic cancer, an area where most cancer drugs often fail. http://www.stockwatch.com/News/Item.aspx?bid=U-z10082871-U%3aPPCH-20140521&symbol=PPCH®ion=U
$PPCH believes this small but significant step supports my initial observations from clinical practice that pancreatic proenzymes have the potential to prolong life and stop tumors from spreading, especially if we treat patients during earlier stages of the disease process".
It is anticipated a number of companies developing cancer stem cell therapies will be presenting at the upcoming 2014 ASCO (American Society of Clinical Oncologists) conference. New effective therapies against cancer stem cells attract significant attention due to their potential to control and inhibit metastatic cancer, an area where most cancer drugs often fail. http://www.stockwatch.com/News/Item.aspx?bid=U-z10082871-U%3aPPCH-20140521&symbol=PPCH®ion=U
"From $PPCH research they observed that pancreatic proenzymes enforce the re-entry of cancer cells into normal cellular pathways and as such, could represent an exciting new method of managing the disease process," said Dr Julian Kenyon, Chief Scientific Officer of Propanc Health Group http://www.stockwatch.com/News/Item.aspx?bid=U-z10082871-U%3aPPCH-20140521&symbol=PPCH®ion=U
"From $PPCH research they observed that pancreatic proenzymes enforce the re-entry of cancer cells into normal cellular pathways and as such, could represent an exciting new method of managing the disease process," said Dr Julian Kenyon, Chief Scientific Officer of Propanc Health Group http://www.stockwatch.com/News/Item.aspx?bid=U-z10082871-U%3aPPCH-20140521&symbol=PPCH®ion=U
$PPCH - Propanc Scientific have received queries regarding the anti-cancer effects and mechanism of action of proenzymes, which we published last year in collaboration with our research partners," said James Nathanielsz, Chief Executive Officer of Propanc Health Group, "Publishing these findings was an important step to gain credibility within the scientific community who recognize the potential of pancreatic proenzymes as a treatment for metastatic cancer." http://www.stockwatch.com/News/Item.aspx?bid=U-z10082871-U%3aPPCH-20140521&symbol=PPCH®ion=U
$PPCH - Propanc Scientific have received queries regarding the anti-cancer effects and mechanism of action of proenzymes, which we published last year in collaboration with our research partners," said James Nathanielsz, Chief Executive Officer of Propanc Health Group, "Publishing these findings was an important step to gain credibility within the scientific community who recognize the potential of pancreatic proenzymes as a treatment for metastatic cancer." http://www.stockwatch.com/News/Item.aspx?bid=U-z10082871-U%3aPPCH-20140521&symbol=PPCH®ion=U
$PPCH - Propanc Scientific announced requests for information regarding the anti-cancer effects of its pancreatic proenzymes treatment ("PRP"), can be accessed via Cellular Oncology, a peer reviewed journal of the International Society for Cellular Oncology http://www.stockwatch.com/News/Item.aspx?bid=U-z10082871-U%3aPPCH-20140521&symbol=PPCH®ion=U
$PPCH - Propanc Scientific announced requests for information regarding the anti-cancer effects of its pancreatic proenzymes treatment ("PRP"), can be accessed via Cellular Oncology, a peer reviewed journal of the International Society for Cellular Oncology http://www.stockwatch.com/News/Item.aspx?bid=U-z10082871-U%3aPPCH-20140521&symbol=PPCH®ion=U
$PPCH - Propanc Scientific announced requests for information regarding the anti-cancer effects of its pancreatic proenzymes treatment ("PRP"), can be accessed via Cellular Oncology, a peer reviewed journal of the International Society for Cellular Oncology http://www.stockwatch.com/News/Item.aspx?bid=U-z10082871-U%3aPPCH-20140521&symbol=PPCH®ion=U
$AHII - American Heritage International is focusing on high volume, long-term relationships across a range of distribution channels, including grocery store distribution groups, mass retailers, tobacco distributors and hotel and casino operators. In addition, the company has developed an online sales platform, through which it aims to drive sales via an aggressive affiliate marketing platform, targeted advertising, forum participation and email marketing. http://www.benzinga.com/14/04/4481506/american-heritage-international-a-strong-competitor-in-a-high-growth-industry#ixzz31bJwMGXX
$AHII - American Heritage International is focusing on high volume, long-term relationships across a range of distribution channels, including grocery store distribution groups, mass retailers, tobacco distributors and hotel and casino operators. In addition, the company has developed an online sales platform, through which it aims to drive sales via an aggressive affiliate marketing platform, targeted advertising, forum participation and email marketing. http://www.benzinga.com/14/04/4481506/american-heritage-international-a-strong-competitor-in-a-high-growth-industry#ixzz31bJwMGXX
$AHII - American Heritage International has an established, competitive product and a rapidly expanding distribution channel in an industry that experts predict will more than treble in size within three years. The company offers investors direct exposure to this growth through the purchase of its stock. http://www.benzinga.com/14/04/4481506/american-heritage-international-a-strong-competitor-in-a-high-growth-industry#ixzz31bHkNQpy
$AHII - American Heritage International has an established, competitive product and a rapidly expanding distribution channel in an industry that experts predict will more than treble in size within three years. The company offers investors direct exposure to this growth through the purchase of its stock. http://www.benzinga.com/14/04/4481506/american-heritage-international-a-strong-competitor-in-a-high-growth-industry#ixzz31bHkNQpy
$AHII - According to the Bloomberg forecast therefore, the e-cigarette industry generate more than $75B in revenues 30 years from now http://www.benzinga.com/14/04/4481506/american-heritage-international-a-strong-competitor-in-a-high-growth-industry#ixzz31bHkNQpy
$AHII - According to the Bloomberg forecast therefore, the e-cigarette industry generate more than $75B in revenues 30 years from now http://www.benzinga.com/14/04/4481506/american-heritage-international-a-strong-competitor-in-a-high-growth-industry#ixzz31bHkNQpy
$CBIS - News! Cannabis Science Issues CBN Patent and R&D Progress Guidance for the 2nd Quarter of 2014 5/22/14 http://www.stockwatch.com/News/Item.aspx?bid=U-prLA33628-U%3aCBIS-20140522&symbol=CBIS®ion=U
$CBIS - News! Cannabis Science Issues CBN Patent and R&D Progress Guidance for the 2nd Quarter of 2014 5/22/14 http://www.stockwatch.com/News/Item.aspx?bid=U-prLA33628-U%3aCBIS-20140522&symbol=CBIS®ion=U
$CBIS - will benefit from Colorado Spending $10 Million Researching Marijuana's Medical Benefits
http://www.huffingtonpost.com/2014/05/21/colorado-medical-marijuana_n_5365644.html?utm_hp_ref=tw
$CBIS - will benefit from Colorado Spending $10 Million Researching Marijuana's Medical Benefits
http://www.huffingtonpost.com/2014/05/21/colorado-medical-marijuana_n_5365644.html?utm_hp_ref=tw
$CBIS - Clinical Studies for Cannabis Based Drug Development Targets Multitude of Medical Treatments - CBIS Issues CBN Patent and R&D Guidance
http://www.marketwatch.com/story/clinical-studies-for-cannabis-based-drug-development-targets-multitude-of-medical-treatments-cbis-issues-cbn-patent-and-rd-guidance-2014-05-22
$CBIS - Clinical Studies for Cannabis Based Drug Development Targets Multitude of Medical Treatments - CBIS Issues CBN Patent and R&D Guidance
http://www.marketwatch.com/story/clinical-studies-for-cannabis-based-drug-development-targets-multitude-of-medical-treatments-cbis-issues-cbn-patent-and-rd-guidance-2014-05-22
$PPCH - Propanc Scientific announced requests for information regarding the anti-cancer effects of its pancreatic proenzymes treatment ("PRP"), can be accessed via Cellular Oncology, a peer reviewed journal of the International Society for Cellular Oncology http://www.stockwatch.com/News/Item.aspx?bid=U-z10082871-U%3aPPCH-20140521&symbol=PPCH®ion=U
$PPCH - Propanc Scientific announced requests for information regarding the anti-cancer effects of its pancreatic proenzymes treatment ("PRP"), can be accessed via Cellular Oncology, a peer reviewed journal of the International Society for Cellular Oncology http://www.stockwatch.com/News/Item.aspx?bid=U-z10082871-U%3aPPCH-20140521&symbol=PPCH®ion=U
$PPCH - Propanc Health Group Corp Profile
http://www.propanc.com/download/Propanc_Health_Group_Profile.pdf
$PPCH - Propanc Health Group Corp Profile
http://www.propanc.com/download/Propanc_Health_Group_Profile.pdf
$CBIS - Clinical Studies for Cannabis Based Drug Development Targets Multitude of Medical Treatments - CBIS Issues CBN Patent and R&D Guidance
http://www.marketwatch.com/story/clinical-studies-for-cannabis-based-drug-development-targets-multitude-of-medical-treatments-cbis-issues-cbn-patent-and-rd-guidance-2014-05-22
$CBIS - Clinical Studies for Cannabis Based Drug Development Targets Multitude of Medical Treatments - CBIS Issues CBN Patent and R&D Guidance
http://www.marketwatch.com/story/clinical-studies-for-cannabis-based-drug-development-targets-multitude-of-medical-treatments-cbis-issues-cbn-patent-and-rd-guidance-2014-05-22
Lol agreed happens to me all the time
$PPCH - Propanc's leading products are novel, patented formulations based on proenzymes, which are inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects http://finance.yahoo.com/news/propanc-health-group-targets-cancer-200000739.html?soc_src=mediacontentstory
$PPCH - Propanc's leading products are novel, patented formulations based on proenzymes, which are inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects http://finance.yahoo.com/news/propanc-health-group-targets-cancer-200000739.html?soc_src=mediacontentstory
$PPCH - Propanc, together with its scientific and oncology consultants, has developed a rational, composite formulation of anti-cancer compounds which together exert a number of anti-cancer actions. http://finance.yahoo.com/news/propanc-health-group-targets-cancer-200000739.html?soc_src=mediacontentstory